Search Results - tlr

2 Results

Sort By:

Personalized Tumor Vaccine and Use Thereof for Cancer Immunotherapy

Abstract: Immune checkpoint inhibitors (ICIs) vastly improved the outcome of various advanced cancers; however, many are less likely to respond to single-agent ICI. Tumors with low T-cell infiltration are "immunologically cold" and less likely to respond to single-agent ICI therapy. This diminished response is presumably due to the lack of neoantigens...

Published: 4/22/2025 | Inventor(s): Zhengping (Ping) Zhuang, Karel Pacak, Jan Zenka, Rogelio Medina, Herui Wang, Sze Chun (Winson) Ho

Keywords(s): Anti-CD40-Monoclonal Antibody, CANCER, ICI, Immune Checkpoint Inhibitors, Mannan-BAM, Oncology, TLR, Toll-like receptor, Tumor Vaccine, Zhuang

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Muramyl Dipeptide as a Therapeutic Agent for Inflammation

The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation...

Published: 10/28/2024 | Inventor(s): Warren Strober

Keywords(s): Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics